No headlines found.
ACCESS Newswire (Tue, 20-Jan 8:05 AM ET)
ACCESS Newswire (Mon, 29-Dec 4:05 PM ET)
ACCESS Newswire (Wed, 24-Dec 8:00 AM ET)
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
ACCESS Newswire (Thu, 4-Dec 8:00 AM ET)
Dermata Therapeutics - Warrant trades on the stock market under the symbol DRMAW.
As of February 27, 2026, DRMAW stock price was flat at $0.02 with million shares trading.
DRMAW has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, DRMAW traded as high as $.07 and as low as $.01.
DRMAW has underperformed the market in the last year with a price return of -32.9% while the SPY ETF gained +18.5%. However, in the short term, DRMAW had mixed performance relative to the market. It has outperformed in the last 3 months, returning +1.6% vs +1.2% return in SPY. But in the last 2 weeks, DRMAW shares have been beat by the market, returning -2.1% compared to an SPY return of +0.6%.
DRMAW support price is $.02 and resistance is $.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRMAW shares will trade within this expected range on the day.
